Navigation Links
VIASPACE Granted US Patent
Date:3/10/2009

PASADENA, Calif., March 10 /PRNewswire-FirstCall/ -- VIASPACE Inc. (OTC Bulletin Board: VSPC) announced today that the United States Patent and Trademark Office issued patent number 7, 499,169 to VIASPACE on March 3, 2009. The patent covers detection and measurement of water vapor (humidity) in gas streams for fuel cells and exhaust streams from combustion processes such as automobiles and factory smokestacks. Inventors are Nathan Hurvitz and VIASPACE CEO Dr. Carl Kukkonen.

VIASPACE's HS-1000 humidity sensor product is now protected by this patent. The HS-1000 uses a laser to make real-time measurements of water vapor in air or other gas streams. Humidity measurements are crucial for testing and optimization of hydrogen fuel cells and the HS-1000 has been sold to leading fuel cell developers and researchers worldwide. The other major application covered by the patent is to measure humidity in the products of combustion. Gasoline or natural gas, when burned in air, produce water vapor as a combustion product. Precise measurement of the water vapor in the exhaust may be a crucial indicator of the efficiency of combustion and the effective "miles per gallon" achieved.

One international customer extensively compared the VIASPACE HS-1000 to two leading competitors and the HS-1000 won the competition. HS-1000 customers include Ballard Power Systems, 3M, US National Renewable Energy Laboratory, Tokyo Institute of Technology and a leading worldwide automobile manufacturer.

About VIASPACE (OTCBB: VSPC) -- VIASPACE was founded in 1998 and became a public company in 2005. VIASPACE focuses on clean and alternative energy including disposable fuel cell cartridges, and a proprietary fast-growing grass as a feedstock for biofuels and for animal feed. For more information, please see www.VIASPACE.com or contact Dr. Jan Vandersande, Director of Communications, at 800-517-8050 or IR@VIASPACE.com.

This news release includes forward-looking statements. These forward-looking statements relate to future events or our future performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Such factors include without limitation the risks outlined in our periodic filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-KSB, for the fiscal year ended December 31, 2007, as well as general economic and business conditions, the ability to acquire and develop specific projects and technologies, the ability to fund operations, changes in consumer and business consumption habits, competition with larger companies, demand for biofuels and animal feed particularly in China, risks associated with international transactions, crop development, growing, and harvesting related risks, and other factors over which VIASPACE has little or no control.


'/>"/>
SOURCE VIASPACE Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIASPACE Plants Biofuel & Animal Feed Grass and Signs Land Lease in China
2. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
3. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
4. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
5. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
6. BioLife Solutions Granted European Biopreservation Patent
7. ScinoPharm Granted US Patent for Novel Crystal Forms
8. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
9. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
10. Autonomy(TM) Lapro-Angle(TM) Articulating Laparoscopic Instruments Granted CE Mark
11. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):